The Impact Of Developmental Haemostasis On The Pharmacokinetics And Pharmacodynamics Of Heparin In Children.
Funder
National Health and Medical Research Council
Funding Amount
$283,676.00
Summary
Unfractionated Heparin (UFH) is the most commonly used anticoagulant (blood thinning drug) in children. Despite this, the clinical evidence, in terms of reported treatment failures and bleeding complications, suggests the drug is used suboptimally in children compared to adults.This likely relfects the lack of specific studies of UFH in children. This study will, for the first time, define the pharmacokinetics-dynamics of UFH in children, allowing age-specific protocols to be developed. Pharmaco ....Unfractionated Heparin (UFH) is the most commonly used anticoagulant (blood thinning drug) in children. Despite this, the clinical evidence, in terms of reported treatment failures and bleeding complications, suggests the drug is used suboptimally in children compared to adults.This likely relfects the lack of specific studies of UFH in children. This study will, for the first time, define the pharmacokinetics-dynamics of UFH in children, allowing age-specific protocols to be developed. Pharmacological modelling of this data will likely have implications for the use of other anticoagulants in children.Read moreRead less
A Study To Determine The Effects Of Heparin/ Low Molecular Weight Heparin In Neonates And Children.
Funder
National Health and Medical Research Council
Funding Amount
$193,000.00
Summary
Blood clots in newborns and children are becoming a more common problem. This is because many children with major illnesses are now surviving due to the remarkable advances in medical and surgical care. Blood clots in children can have devastating long term effects. Little is known about the best way to treat blood clots in children and most treatments are just extrapolated from adult treatment guidelines. This is unlikely to be the best treatment as the type and place of blood clots in children ....Blood clots in newborns and children are becoming a more common problem. This is because many children with major illnesses are now surviving due to the remarkable advances in medical and surgical care. Blood clots in children can have devastating long term effects. Little is known about the best way to treat blood clots in children and most treatments are just extrapolated from adult treatment guidelines. This is unlikely to be the best treatment as the type and place of blood clots in children are very different to adults. In addition, the blood clotting system in children is very different to that in adults. This is especially true for newborns. Over the last four years we have established the largest clinical treatment program for children with blood clots in Australia, and have completed the preliminary work that will enable us to now study a number of aspects of the treatment for blood clots in children. This project will specifically examine heparin and low molecular weight heparin which are the most commonly used antithrombotic (anti blood clot) drugs in children. We will determine the effect of age on the mechanism of action, the optimal drug level for treatment, the frequency of the most common side effect of heparin and do some preliminary work to determine alternative treatment options. Our study will provide the basis for more appropriate use of these drugs in children, which will improve the success of therapy and reduce the risk of complications, ultimately improving the survival and quality of life for sick children affected by blood clots.Read moreRead less